Arecor Therapeutics Plc

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: GB00BMWLM973

GBP

0.74

0.02 (2.07%)

Dec 04

LON

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

ECO Animal Health Group Plc

Shield Therapeutics Plc

Alliance Pharma Plc

Arecor Therapeutics Plc

Redx Pharma Plc

Indivior PLC

Destiny Pharma Plc

Benchmark Holdings Plc

Dechra Pharmaceuticals Plc

GSK Plc

AstraZeneca PLC

Why is Arecor Therapeutics Plc ?

Flat results in Jun 24

ROCE(HY) Lowest at -94.76%
CASH AND EQV(HY) Lowest at GBP 2.54 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -3.27%, its profits have fallen by -2470%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -3.27% returns in the last 1 year, the stock has also underperformed FTSE 100 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Arecor Therapeutics Plc for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Arecor Therapeutics Plc

-3.27%

-0.92

45.51%

FTSE 100

15.94%

1.23

12.99%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.40%

EBIT Growth (5y)

1.37%

EBIT to Interest (avg)

-4.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.59

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

11.44

EV to EBIT

-10.18

EV to EBITDA

-10.75

EV to Capital Employed

28.49

EV to Sales

30.89

PEG Ratio

Dividend Yield

ROCE (Latest)

-279.78%

ROE (Latest)

-835.91%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Arecor Therapeutics Plc

Net Profit

Higher at GBP -4.64 MM

than preceding 12 month period ended Jun 2024

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (GBP MM)

Here's what is not working for Arecor Therapeutics Plc

Cash and Eqv

Lowest at GBP 2.54 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents